Reproductive Health — MCQs
On this page
A 38-year-old woman with body mass index of 42 kg/m² requests contraception. She has a history of previous deep vein thrombosis 2 years ago associated with long-haul flight. Thrombophilia screening was negative. She has essential hypertension controlled on ramipril with blood pressure today of 138/88 mmHg. She is a non-smoker. Which contraceptive method would be most suitable?
A 49-year-old woman on sequential combined HRT presents with a 3-day episode of vaginal bleeding on day 18 of her cycle. She started this HRT regimen 10 months ago for vasomotor symptoms. She takes 2 mg estradiol daily with 10 mg dydrogesterone on days 15-28 of each 28-day cycle. Her previous bleeding pattern showed withdrawal bleeds on days 22-26. What is the most appropriate next step in management?
A 46-year-old woman presents with worsening hot flushes and night sweats over the past 4 months. Her periods have become irregular, occurring every 6-8 weeks. She has a history of breast cancer treated with wide local excision and radiotherapy 3 years ago, now in remission. She is currently taking tamoxifen. She requests HRT for symptom control. What is the most appropriate management?
A 31-year-old woman with Crohn's disease had the etonogestrel implant inserted 10 months ago. She presents with a 4-month history of frequent irregular bleeding, occurring every 10-14 days and lasting 5-7 days. She reports no abdominal pain and her Crohn's disease is well controlled. She wishes to continue with the implant. What is the most appropriate management to address the bleeding pattern?
A 51-year-old woman commenced on continuous combined HRT 8 months ago presents with light vaginal bleeding for 3 days. She reports good control of her menopausal symptoms. Her last natural menstrual period was 14 months ago. On examination, her blood pressure is 128/82 mmHg and abdominal and pelvic examination are unremarkable. What is the most appropriate next step in management?
A 29-year-old woman with factor V Leiden mutation attends for contraceptive counseling. She is in a stable relationship and wishes to avoid pregnancy for the next 3 years. Her BMI is 23 kg/m², blood pressure is 116/74 mmHg, and she is a non-smoker. She has regular menstrual cycles and no dysmenorrhea. Which contraceptive method is most appropriate for her?
A 54-year-old woman who underwent hysterectomy for fibroids 5 years ago presents with severe vasomotor symptoms affecting her quality of life. She has no personal or family history of breast cancer or venous thromboembolism. Her BMI is 28 kg/m² and blood pressure is 132/84 mmHg. What is the most appropriate hormone replacement therapy regimen for this patient?
A 47-year-old woman presents with a 3-month history of irregular menstrual cycles, previously regular 28-day cycles. She reports occasional hot flushes. Her last menstrual period was 6 weeks ago. She requests hormonal contraception. Her BMI is 26 kg/m² and blood pressure is 124/78 mmHg. She is a non-smoker with no significant medical history. What is the most appropriate initial contraceptive advice?
A 22-year-old woman requests contraception. She has no significant medical history and is a non-smoker. Her BMI is 24 kg/m². She mentions she sometimes forgets to take medications regularly. On examination, her blood pressure is 118/76 mmHg. Which contraceptive method would provide the longest duration of action with a single administration?
A 53-year-old woman on continuous combined HRT for 2 years presents with bilateral breast tenderness and reports feeling a lump in her right breast. Examination reveals diffuse nodularity bilaterally and a 2 cm smooth, mobile lump in the upper outer quadrant of the right breast. She is up to date with breast screening; her last mammogram 10 months ago showed dense breast tissue with no abnormalities. What is the most appropriate management?
Reproductive Health UK Medical PG Practice Questions and MCQs
Question 141: A 38-year-old woman with body mass index of 42 kg/m² requests contraception. She has a history of previous deep vein thrombosis 2 years ago associated with long-haul flight. Thrombophilia screening was negative. She has essential hypertension controlled on ramipril with blood pressure today of 138/88 mmHg. She is a non-smoker. Which contraceptive method would be most suitable?
- A. Levonorgestrel intrauterine system (Correct Answer)
- B. Vaginal contraceptive ring
- C. Depot medroxyprogesterone acetate
- D. Combined oral contraceptive pill
- E. Transdermal contraceptive patch
Explanation: ***Levonorgestrel intrauterine system*** - The **LNG-IUS** is classified as **UKMEC 1** for patients with a history of **venous thromboembolism (VTE)** because it is a progestogen-only method with minimal systemic absorption, not increasing the risk of recurrence. - It is highly suitable for this patient as it is not affected by her **BMI of 42 kg/m²** or her controlled **hypertension**, offering superior efficacy and the additional benefit of reduced menstrual bleeding. *Vaginal contraceptive ring* - This is a **combined hormonal contraceptive (CHC)**, containing estrogen, and is therefore categorized as **UKMEC 4** (absolute contraindication) due to the patient's history of **deep vein thrombosis (DVT)**. - CHCs significantly increase the synthesis of clotting factors, substantially elevating the risk of recurrent **thromboembolic events**. *Depot medroxyprogesterone acetate* - Although **depot medroxyprogesterone acetate (DMPA)** is a progestogen-only method and does not increase VTE risk, it is often avoided in morbidly obese patients (**BMI >40 kg/m²**) due to its association with significant **weight gain**. - While classified as **UKMEC 2** in this context, the potential for further weight gain makes it less ideal than the IUS given her existing BMI and cardiovascular risk factors. *Combined oral contraceptive pill* - The **COCP** is strictly contraindicated (**UKMEC 4**) in any woman with a previous history of **VTE**, regardless of whether the event was provoked or unprovoked, due to its **estrogen** component. - Her **BMI >35 kg/m²** and controlled **hypertension** are also independent **UKMEC 3** criteria, making this method unsafe and highly unsuitable for her. *Transdermal contraceptive patch* - Similar to the pill and ring, the **transdermal patch** contains **estrogen**, which is absolutely contraindicated (**UKMEC 4**) in patients with a history of **DVT**. - The efficacy of the **transdermal patch** may also be reduced in women weighing more than 90 kg, which is highly probable given her **BMI of 42 kg/m²**.
Question 142: A 49-year-old woman on sequential combined HRT presents with a 3-day episode of vaginal bleeding on day 18 of her cycle. She started this HRT regimen 10 months ago for vasomotor symptoms. She takes 2 mg estradiol daily with 10 mg dydrogesterone on days 15-28 of each 28-day cycle. Her previous bleeding pattern showed withdrawal bleeds on days 22-26. What is the most appropriate next step in management?
- A. Switch to continuous combined HRT
- B. Continue current regimen and review in 3 months
- C. Arrange transvaginal ultrasound scan (Correct Answer)
- D. Increase the progestogen dose
- E. Refer for urgent endometrial biopsy
Explanation: ***Arrange transvaginal ultrasound scan*** - In women on **sequential combined HRT**, bleeding that occurs outside the expected withdrawal period or a **change in an established bleeding pattern** requires investigation to rule out endometrial pathology. - A **transvaginal ultrasound (TVUS)** is the first-line investigation to assess **endometrial thickness** and check for structural issues like polyps before considering invasive biopsies. *Switch to continuous combined HRT* - This patient began HRT only 10 months ago and is likely **perimenopausal**; switching to continuous combined HRT is usually reserved for women who are **postmenopausal** for at least one year. - Switching regimens would be inappropriate before investigating the cause of the **unscheduled bleeding** to ensure a malignancy is not being masked. *Continue current regimen and review in 3 months* - While **breakthrough bleeding** is common in the first 6 months of HRT, this patient has been on her regimen for 10 months and has a **new change** in her bleeding pattern. - Expectant management is inappropriate when a stable bleeding pattern changes, as it delays the diagnosis of potential **endometrial hyperplasia** or cancer. *Increase the progestogen dose* - Increasing the **progestogen dose** is a strategy to manage breakthrough bleeding, but it should only be done after **pathology** has been excluded via imaging. - Adjusting doses without investigation risks providing a false sense of security while an underlying **endometrial abnormality** persists. *Refer for urgent endometrial biopsy* - While an **endometrial biopsy** may eventually be needed, it is typically indicated if the **TVUS** shows an endometrial thickness >7mm or other irregularities. - An **urgent 2-week wait referral** is generally reserved for true **postmenopausal bleeding (PMB)** or persistent unscheduled bleeding where malignancy is highly suspected.
Question 143: A 46-year-old woman presents with worsening hot flushes and night sweats over the past 4 months. Her periods have become irregular, occurring every 6-8 weeks. She has a history of breast cancer treated with wide local excision and radiotherapy 3 years ago, now in remission. She is currently taking tamoxifen. She requests HRT for symptom control. What is the most appropriate management?
- A. Prescribe standard dose continuous combined HRT
- B. Recommend cognitive behavioural therapy and lifestyle modifications (Correct Answer)
- C. Prescribe tibolone
- D. Prescribe low-dose oestrogen-only HRT
- E. Stop tamoxifen and commence HRT
Explanation: ***Recommend cognitive behavioural therapy and lifestyle modifications*** - Systemic **HRT is contraindicated** in patients with a history of **breast cancer** (UKMEC 4) due to the risk of stimulating residual malignant cells and increasing **recurrence risk**. - **Cognitive Behavioural Therapy (CBT)** and lifestyle changes are the evidence-based first-line non-hormonal management strategies for **vasomotor symptoms** in cancer survivors. *Prescribe standard dose continuous combined HRT* - Oestrogen-containing therapy poses an **unacceptable health risk** for women with a history of oestrogen-sensitive malignancies like breast cancer. - Combined HRT is also only appropriate for patients who have been **amenorrhoeic for at least 12 months** to avoid irregular breakthrough bleeding, and this patient still has irregular periods. *Prescribe tibolone* - **Tibolone** is a synthetic steroid with oestrogenic, progestogenic, and androgenic properties that is specifically **contraindicated** in breast cancer survivors. - Clinical trials (like the **LIBERATE study**) demonstrated that tibolone significantly increases the risk of **breast cancer recurrence**. *Prescribe low-dose oestrogen-only HRT* - **Oestrogen-only HRT** is contraindicated in women with an **intact uterus** as it leads to endometrial hyperplasia and increases the risk of **endometrial cancer**. - Regardless of dose, systemic oestrogen should be avoided in this patient due to her **breast cancer history**. *Stop tamoxifen and commence HRT* - **Tamoxifen** is a vital **selective estrogen receptor modulator (SERM)** used to prevent recurrence in breast cancer and should not be discontinued for symptom management. - Tamoxifen itself can worsen **vasomotor symptoms**, but these should be managed with non-hormonal alternatives rather than stopping **life-saving oncology treatment**.
Question 144: A 31-year-old woman with Crohn's disease had the etonogestrel implant inserted 10 months ago. She presents with a 4-month history of frequent irregular bleeding, occurring every 10-14 days and lasting 5-7 days. She reports no abdominal pain and her Crohn's disease is well controlled. She wishes to continue with the implant. What is the most appropriate management to address the bleeding pattern?
- A. Prescribe mefenamic acid during bleeding episodes (Correct Answer)
- B. Prescribe tranexamic acid during bleeding episodes
- C. Reassure that bleeding will settle spontaneously
- D. Remove the implant and insert a new one
- E. Prescribe combined oral contraceptive pill for 3 months
Explanation: ***Prescribe mefenamic acid during bleeding episodes***- **Mefenamic acid** is a first-line medical intervention for managing irregular bleeding associated with the **etonogestrel implant** by reducing prostaglandin levels in the endometrium.- It is a suitable option for this patient because her **Crohn's disease** (even if well-controlled) may represent a relative contraindication or increased risk for estrogen-based therapies.*Prescribe tranexamic acid during bleeding episodes*- **Tranexamic acid** is primarily indicated for **heavy menstrual bleeding** (menorrhagia) rather than the frequent, irregular spotting typical of hormonal implants.- While it can be used, evidence suggests it is generally less effective than **NSAIDs** like mefenamic acid for implant-related bleeding disturbances.*Reassure that bleeding will settle spontaneously*- Bleeding patterns with the implant usually stabilize within the first **3 to 6 months**; since she is at 10 months, spontaneous improvement is unlikely.- **Active management** is required here because the patient is seeking help for a persistent problem that has lasted 4 months.*Remove the implant and insert a new one*- **Early replacement** of the etonogestrel implant does not resolve bleeding issues, as the bleeding is a physiological side effect of the **progestogen-only** delivery.- This approach is not evidence-based and would unnecessarily expose the patient to surgical procedures and **medical costs**.*Prescribe combined oral contraceptive pill for 3 months*- Although a **COCP** is often used to stabilize the endometrium, it contains **estrogen**, which increases the risk of **venous thromboembolism (VTE)**.- This is specifically avoided in patients with **Crohn's disease** due to the associated baseline increase in **prothrombotic risk**, making mefenamic acid a safer choice.
Question 145: A 51-year-old woman commenced on continuous combined HRT 8 months ago presents with light vaginal bleeding for 3 days. She reports good control of her menopausal symptoms. Her last natural menstrual period was 14 months ago. On examination, her blood pressure is 128/82 mmHg and abdominal and pelvic examination are unremarkable. What is the most appropriate next step in management?
- A. Reassure her that irregular bleeding is common in the first year of continuous combined HRT
- B. Arrange urgent transvaginal ultrasound and refer to gynecology (Correct Answer)
- C. Switch to sequential combined HRT
- D. Arrange pelvic ultrasound within 2 weeks
- E. Increase the progestogen component of her HRT
Explanation: ***Arrange urgent transvaginal ultrasound and refer to gynecology*** - The patient has been on continuous combined HRT for **8 months**, which exceeds the **initial 6-month period** during which irregular bleeding is often considered acceptable. - Any unscheduled or persistent vaginal bleeding in a postmenopausal woman on HRT after 6 months must be urgently investigated to rule out **endometrial pathology**, including **endometrial cancer**, typically via a **transvaginal ultrasound** and **gynecological referral**. *Reassure her that irregular bleeding is common in the first year of continuous combined HRT* - While irregular bleeding can be common during the initial adjustment to continuous combined HRT, this typically applies only to the **first 3-6 months**. - Beyond this timeframe, unscheduled bleeding in a postmenopausal woman requires investigation as it is considered **postmenopausal bleeding (PMB)** and carries a risk of underlying **endometrial pathology**. *Switch to sequential combined HRT* - **Sequential combined HRT** is generally used for perimenopausal women or those who prefer cyclical bleeding, and switching to it would not address the urgent need to investigate the current **unscheduled bleeding**. - Adjusting the HRT type without first excluding serious **endometrial conditions** or malignancy is clinically inappropriate and may delay critical diagnosis. *Arrange pelvic ultrasound within 2 weeks* - While a **pelvic ultrasound** (specifically transvaginal) is a necessary diagnostic tool, the situation demands an **urgent referral** to gynecology, often within a **2-week wait pathway**, for comprehensive evaluation. - Simply arranging an ultrasound without the accompanying specialist referral for suspected **postmenopausal bleeding** does not fully meet the standard of care. *Increase the progestogen component of her HRT* - Increasing the **progestogen** component may be considered for managing benign breakthrough bleeding, but only **after** serious endometrial pathology, such as **endometrial hyperplasia** or cancer, has been definitively ruled out. - Without prior investigation, adjusting the hormonal dose risks masking symptoms of a significant underlying condition and delaying appropriate management.
Question 146: A 29-year-old woman with factor V Leiden mutation attends for contraceptive counseling. She is in a stable relationship and wishes to avoid pregnancy for the next 3 years. Her BMI is 23 kg/m², blood pressure is 116/74 mmHg, and she is a non-smoker. She has regular menstrual cycles and no dysmenorrhea. Which contraceptive method is most appropriate for her?
- A. Combined oral contraceptive pill
- B. Copper intrauterine device (Correct Answer)
- C. Vaginal contraceptive ring
- D. Transdermal contraceptive patch
- E. Progesterone-only pill (desogestrel)
Explanation: ***Copper intrauterine device*** - The **copper intrauterine device (Cu-IUD)** contains no hormones and carries no increased risk of **venous thromboembolism (VTE)**, making it ideal for patients with **Factor V Leiden mutation**. - It is a highly effective **long-acting reversible contraceptive (LARC)** that provides protection for up to 10 years, satisfying her desire to avoid pregnancy for 3 years.*Combined oral contraceptive pill* - The **oestrogen** component in combined pills significantly increases the risk of **VTE**, which is synergistically elevated in patients with **thrombophilias** like **Factor V Leiden**. - It is classified as **UKMEC 4** (unacceptable health risk) for women with known thrombogenic mutations.*Vaginal contraceptive ring* - Like the combined pill, the vaginal ring contains **oestrogen** and is contraindicated in women with an increased baseline risk of **thrombosis**. - It carries a similar **thrombotic risk profile** to other combined hormonal delivery systems, regardless of the route of administration.*Transdermal contraceptive patch* - The patch delivers **ethinylestradiol** systemically, which leads to an increased production of **clotting factors** by the liver. - It is strictly **contraindicated** in this patient due to her underlying **coagulopathy** and the risk of life-threatening thromboembolic events.*Progesterone-only pill (desogestrel)* - While the **progesterone-only pill (POP)** is safe in Factor V Leiden as it does not increase **VTE risk**, it is generally less effective in typical use compared to **LARCs**. - The **copper IUD** is often preferred over the POP for long-term planning (3 years) as it eliminates the need for daily adherence and offers superior **contraceptive efficacy**.
Question 147: A 54-year-old woman who underwent hysterectomy for fibroids 5 years ago presents with severe vasomotor symptoms affecting her quality of life. She has no personal or family history of breast cancer or venous thromboembolism. Her BMI is 28 kg/m² and blood pressure is 132/84 mmHg. What is the most appropriate hormone replacement therapy regimen for this patient?
- A. Continuous combined oestrogen and progesterone therapy
- B. Sequential combined oestrogen and progesterone therapy
- C. Oestrogen-only therapy (Correct Answer)
- D. Progesterone-only therapy
- E. Tibolone
Explanation: ***Oestrogen-only therapy*** - In women who have undergone a **hysterectomy**, there is no **endometrium** to protect from the stimulatory effects of oestrogen, making progestogens unnecessary. - **Oestrogen-only HRT** is the most effective treatment for **vasomotor symptoms** (hot flashes and night sweats) and has a lower risk profile regarding breast cancer compared to combined therapy. *Continuous combined oestrogen and progesterone therapy* - This regimen is indicated for postmenopausal women with an **intact uterus** to prevent **endometrial hyperplasia** and cancer. - Adding **progesterone** in this patient would provide no clinical benefit and would unnecessarily increase the risk of certain side effects like **breast cancer**. *Sequential combined oestrogen and progesterone therapy* - This approach is typically used for perimenopausal women with an **intact uterus** to provide regular **withdrawal bleeds**. - Since this patient has no uterus, there is no need for **endometrial protection** or a induced bleeding cycle. *Progesterone-only therapy* - **Progesterone-only** options are not the standard of care or first-line choice for treating **vasomotor symptoms** in the absence of a uterus. - Its primary use in hormone therapy is to counteract the effects of oestrogen on the **endometrium**, which is not required here. *Tibolone* - **Tibolone** is a synthetic compound with oestrogenic, progestogenic, and androgenic properties that can be used post-hysterectomy. - However, **oestrogen-only therapy** is generally preferred as the first-line treatment for severe vasomotor symptoms due to more robust efficacy data and a favorable risk-benefit profile.
Question 148: A 47-year-old woman presents with a 3-month history of irregular menstrual cycles, previously regular 28-day cycles. She reports occasional hot flushes. Her last menstrual period was 6 weeks ago. She requests hormonal contraception. Her BMI is 26 kg/m² and blood pressure is 124/78 mmHg. She is a non-smoker with no significant medical history. What is the most appropriate initial contraceptive advice?
- A. She should use barrier methods only until menopause is confirmed
- B. Combined hormonal contraception is contraindicated due to her age
- C. She can use combined hormonal contraception and should continue until age 50 (Correct Answer)
- D. Progesterone-only methods are the only suitable options at her age
- E. She no longer needs contraception as she is perimenopausal
Explanation: ***She can use combined hormonal contraception and should continue until age 50***- Per **FSRH guidelines**, healthy non-smoking women with a BMI <35 kg/m² and no other risk factors can safely use **combined oral contraception (COC)** up to the age of 50.- In this perimenopausal patient, **combined hormonal contraception** not only provides effective birth control but also helps manage symptoms such as **hot flushes** and **irregular menstrual cycles**.*She should use barrier methods only until menopause is confirmed*- Barrier methods are an option, but they are not the only choice for a healthy woman under 50; they have a higher **failure rate** compared to hormonal methods.- Resting on barrier methods alone ignores the beneficial effects of hormonal treatments on **vasomotor symptoms** and bone health during the perimenopause.*Combined hormonal contraception is contraindicated due to her age*- Age alone is not a contraindication; **UKMEC 1** or 2 criteria often apply to women over 40 long as they are non-smokers and lack significant cardiovascular risk.- Modern low-dose **estrogen** formulations have significantly reduced the risks historically associated with COC use in older reproductive-age women.*Progesterone-only methods are the only suitable options at her age*- While **progestogen-only pills (POP)** or implants are excellent choices, they are not the *only* choice as combined methods are permissible until age 50.- Progestogen-only methods do not consistently provide the **estrogenic support** needed to control perimenopausal symptoms like hot flushes.*She no longer needs contraception as she is perimenopausal*- Women are considered potentially fertile until they have been **amenorrheic** for at least two years if under 50, or one year if over 50.- Although fertility declines with age, **spontaneous pregnancy** is still possible during the perimenopause, making reliable contraception essential.
Question 149: A 22-year-old woman requests contraception. She has no significant medical history and is a non-smoker. Her BMI is 24 kg/m². She mentions she sometimes forgets to take medications regularly. On examination, her blood pressure is 118/76 mmHg. Which contraceptive method would provide the longest duration of action with a single administration?
- A. Copper intrauterine device (Correct Answer)
- B. Levonorgestrel intrauterine system (52mg)
- C. Etonogestrel subdermal implant
- D. Depot medroxyprogesterone acetate injection
- E. Combined oral contraceptive pill
Explanation: ***Copper intrauterine device***- The **copper IUD** (Cu-IUD) provides the longest duration of action among the options, with many devices licensed for up to **10 years** of continuous use.- It is a highly effective **Long-Acting Reversible Contraceptive (LARC)** that eliminates the need for daily adherence, making it ideal for patients who forget medications.*Levonorgestrel intrauterine system (52mg)*- The 52mg **LNG-IUS** (e.g., Mirena) is typically licensed for **5 to 6 years** for contraception, which is shorter than the 10-year copper IUD.- While it provides secondary benefits like **reduced menstrual bleeding**, it does not meet the criteria for the longest possible single-administration duration.*Etonogestrel subdermal implant*- The **subdermal implant** (e.g., Nexplanon) is a LARC that provides highly effective contraception for a duration of **3 years**.- Although it has the **lowest failure rate** of all methods, it requires replacement much sooner than the copper IUD or the 52mg LNG-IUS.*Depot medroxyprogesterone acetate injection*- This method requires a repeat intramuscular or subcutaneous injection every **12 to 13 weeks** to maintain efficacy.- It is not considered a true "set and forget" method for years and is associated with a **delay in the return of fertility**.*Combined oral contraceptive pill*- This method requires **daily administration** at approximately the same time, making it the least suitable for a patient who mentions forgetting medications.- It is a **short-acting** method and has a significantly higher typical-use failure rate compared to LARC methods like the IUD or implant.
Question 150: A 53-year-old woman on continuous combined HRT for 2 years presents with bilateral breast tenderness and reports feeling a lump in her right breast. Examination reveals diffuse nodularity bilaterally and a 2 cm smooth, mobile lump in the upper outer quadrant of the right breast. She is up to date with breast screening; her last mammogram 10 months ago showed dense breast tissue with no abnormalities. What is the most appropriate management?
- A. Refer urgently via two-week wait pathway for triple assessment (Correct Answer)
- B. Stop HRT for 6 weeks and review; if lump persists, refer for imaging
- C. Arrange ultrasound of the breast lump in the next few weeks
- D. Reduce HRT dose and prescribe evening primrose oil for breast tenderness
- E. Reassure and arrange routine follow-up in 6 months as recent mammogram was normal
Explanation: ***Refer urgently via two-week wait pathway for triple assessment*** - NICE guidelines mandate an urgent **two-week wait (2WW) referral** for any woman aged 30 or older presenting with an **unexplained, new discrete breast lump**. - A normal mammogram within the last year does not exclude malignancy, as **dense breast tissue** (noted here) can frequently mask small or developing cancers. *Stop HRT for 6 weeks and review; if lump persists, refer for imaging* - Delaying referral to observe the effects of stopping **hormone replacement therapy (HRT)** is dangerous and deviates from standard **cancer referral pathways**. - While HRT can cause generalized **nodularity** and tenderness, a **discrete 2 cm lump** must be investigated immediately to ensure it is not malignant. *Arrange ultrasound of the breast lump in the next few weeks* - Standard primary care investigations like a simple ultrasound are insufficient for a **new palpable lump**; the patient requires a specialist **triple assessment** (clinical examination, imaging, and potential biopsy). - Ordering tests outside of the **2WW pathway** leads to clinical delay and does not meet the necessary standard of care for suspected malignancy. *Reduce HRT dose and prescribe evening primrose oil for breast tenderness* - Reducing the dose and using **evening primrose oil** may address the **bilateral tenderness**, but it clinically ignores the presence of the **discrete mobile lump**. - Symptomatic relief of mastalgia should only be prioritized after a **malignant process** has been formally excluded by specialist referral. *Reassure and arrange routine follow-up in 6 months as recent mammogram was normal* - Reassurance is inappropriate because a **palpable clinical finding** takes precedence over a previous imaging report, especially when the tissue is **dense**. - Approximately **10-15% of breast cancers** are mammographically occult, making clinical progression the primary indicator for a new urgent referral.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free